Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$1.41B |
| 2 |
ExxonMobil
XOM
|
+$937M |
| 3 |
Eli Lilly
LLY
|
+$875M |
| 4 |
Tesla
TSLA
|
+$749M |
| 5 |
GE Aerospace
GE
|
+$740M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$1.99B |
| 2 |
Deutsche Bank
DB
|
+$1.49B |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$1.12B |
| 4 |
Broadcom
AVGO
|
+$1.12B |
| 5 |
Amgen
AMGN
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.51% |
| 2 | Healthcare | 16.3% |
| 3 | Consumer Discretionary | 11.31% |
| 4 | Industrials | 10.9% |
| 5 | Financials | 9.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Diamondback Energy
FANG
$56.2B
| $185M | 0.06% |
1,523,289
-610,436
| -29% | -$83.7M |
|
227
Amphenol
APH
$210B
| $181M | 0.06% |
5,628,118
-12,496,846
| -69% | -$434M |
|
|
LGF.B
228
DELISTED
Lions Gate Entertainment Corp. Class B Non-Voting Shares
LGF.B
| $177M | 0.06% |
20,015,435
+7,883,456
| +65% | +$89.8M |
|
|
SRCL
229
DELISTED
Stericycle Inc
SRCL
| $176M | 0.05% |
4,019,153
-377,805
| -9% | -$18.7M |
|
230
Cognizant
CTSH
$26.2B
| $176M | 0.05% |
2,609,024
-8,010,567
| -75% | -$613M |
|
|
EA
231
DELISTED
Electronic Arts
EA
| $174M | 0.05% |
1,432,528
+9,740
| +0.7% | +$1.24M |
|
232
Alibaba
BABA
$300B
| $172M | 0.05% |
+1,509,110
| New | +$148M |
|
233
Suncor Energy
SU
$74.7B
| $171M | 0.05% |
4,862,043
+3,164
| +0.1% | +$115K |
|
|
IBTX
234
DELISTED
Independent Bank Group, Inc.
IBTX
| $166M | 0.05% |
2,446,602
-596,380
| -20% | -$41.6M |
|
235
Shell
SHEL
$249B
| $162M | 0.05% |
3,090,256
-1,684,448
| -35% | -$94.6M |
|
236
Pegasystems
PEGA
$5.15B
| $161M | 0.05% |
6,736,102
+2,451,008
| +57% | +$73.3M |
|
237
Matsons
MATX
$6.41B
| $157M | 0.05% |
2,157,874
+53,000
| +3% | +$4.56M |
|
238
SentinelOne
S
$7.64B
| $156M | 0.05% |
6,692,881
+314,783
| +5% | +$8.83M |
|
239
DraftKings
DKNG
$12.7B
| $156M | 0.05% |
13,372,787
+5,741,987
| +75% | +$80.9M |
|
240
Bank of America
BAC
$453B
| $154M | 0.05% |
4,957,015
-4,637,381
| -48% | -$167M |
|
|
HCP
241
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
| $153M | 0.05% |
5,205,998
+3,721,626
| +251% | +$150M |
|
242
Pfizer
PFE
$150B
| $152M | 0.05% |
2,902,264
+1,397,525
| +93% | +$71.2M |
|
243
BWX Technologies
BWXT
$15.8B
| $151M | 0.05% |
2,738,732
+105,898
| +4% | +$5.51M |
|
244
West Pharmaceutical
WST
$24.8B
| $150M | 0.05% |
494,635
+155
| +0% | +$50.4K |
|
245
Johnson & Johnson
JNJ
$629B
| $147M | 0.05% |
827,157
-222
| -0% | -$39.6K |
|
246
CONMED
CNMD
$1.48B
| $147M | 0.05% |
1,530,589
+391,233
| +34% | +$47M |
|
247
Euronet Worldwide
EEFT
$2.66B
| $144M | 0.04% |
1,431,928
+309,926
| +28% | +$36.7M |
|
248
British American Tobacco
BTI
$120B
| $142M | 0.04% |
3,310,449
+6,489
| +0.2% | +$278K |
|
249
PagSeguro Digital
PAGS
$2.4B
| $142M | 0.04% |
13,850,878
-17,367,576
| -56% | -$249M |
|
|
B
250
Barrick Mining
B
$67.9B
| $132M | 0.04% |
7,486,475
+846
| +0% | +$18.4K |
|
Similar funds
Capital Research Global Investors's Q2 2022 Portfolio in Review
As of Q2 2022, Capital Research Global Investors held 461 positions worth $321B, down 21% from $405B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Capital Research Global Investors withdrew a net $12.2B in Q2 2022, closing 38 positions and reducing 158 holdings. Its most notable exit was Deutsche Bank, an estimated $1.49B position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Capital Research Global Investors opened a new position in Eli Lilly worth $945M.
- Capital Research Global Investors's largest Q2 2022 buy was Eli Lilly: 2,914,107 shares worth $945M.
- Capital Research Global Investors added most to AbbVie in Q2 2022, an estimated $1.41B increase.
- Capital Research Global Investors's biggest Q2 2022 reduction was JPMorgan Chase, cutting an estimated $1.99B.
- Capital Research Global Investors fully exited Deutsche Bank in Q2 2022, selling an estimated $1.49B.
- Capital Research Global Investors's ten largest holdings make up 29% of its $321B portfolio in Q2 2022.
- Capital Research Global Investors opened 21 new positions and closed 38 in Q2 2022.
- Capital Research Global Investors's portfolio value fell 21% quarter-over-quarter to $321B.
Based on Capital Research Global Investors's 13F filing for Q2 2022, filed 15 Aug 2022.